(IMVT) Immunovant - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 5.056m USD | Total Return: 71% in 12m

Antibodies, Treatments, Diseases
Total Rating 39
Safety 34
Buy Signal -0.15
Biotechnology
Industry Rotation: +3.7
Market Cap: 5.06B
Avg Turnover: 28.3M USD
ATR: 5.21%
Peers RS (IBD): 47.8
Risk 5d forecast
Volatility50.3%
Rel. Tail Risk-7.65%
Reward TTM
Sharpe Ratio1.17
Alpha28.12
Character TTM
Beta1.180
Beta Downside1.004
Drawdowns 3y
Max DD69.88%
CAGR/Max DD0.27
EPS (Earnings per Share) EPS (Earnings per Share) of IMVT over the last years for every Quarter: "2021-03": -0.29, "2021-06": -0.31, "2021-09": -0.35, "2021-12": -0.36, "2022-03": -0.41, "2022-06": -0.35, "2022-09": -0.41, "2022-12": -0.49, "2023-03": -0.46, "2023-06": -0.57, "2023-09": -0.45, "2023-12": -0.36, "2024-03": -0.52, "2024-06": -0.6, "2024-09": -0.74, "2024-12": -0.76, "2025-03": -0.64, "2025-06": -0.71, "2025-09": -0.73, "2025-12": -0.5373,
EPS CAGR: -9.63%
EPS Trend: -76.4%
Last SUE: 2.56
Qual. Beats: 1
Revenue Revenue of IMVT over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0, 2024-03: 1.5, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0.16, 2025-06: 0, 2025-09: 0, 2025-12: 0,
Rev. CAGR: 0.00%
Rev. Trend: 6.2%
Last SUE: 0.00
Qual. Beats: 0

Warnings

Share dilution 23.5% YoY - potential capital distress

Beneish M-Score 0.85 > -1.5 - likely earnings manipulation

Altman Z'' -15.00 < 1.0 - financial distress zone

Choppy

Tailwinds

No distinct edge detected

Description: IMVT Immunovant

Immunovant, Inc. (IMVT) is a clinical-stage biotechnology company focused on developing monoclonal antibodies for autoimmune diseases. The companys pipeline includes IMVT-1402, targeting multiple conditions such as Graves disease and rheumatoid arthritis, and batoclimab, for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The biotechnology sector is characterized by lengthy and expensive drug development processes.

Founded in 2018, Immunovant operates as a subsidiary of Roivant Sciences Ltd. Its business model involves the research and development of novel therapeutic candidates, which typically requires significant capital investment before potential commercialization. Further research on platforms like ValueRay can provide deeper insights into IMVTs financial health and market position.

Headlines to Watch Out For
  • IMVT-1402 clinical trial results impact future revenue streams
  • Batoclimab regulatory approval drives market penetration
  • Competition in autoimmune disease market affects pricing power
  • R&D expenses for novel antibodies influence profitability
  • Roivant Sciences strategic decisions impact Immunovants valuation
Piotroski VR‑10 (Strict) 0.0
Net Income: -464.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.40 > 0.02 and ΔFCF/TA 37.16 > 1.0
NWC/Revenue: 610k% < 20% (prev 22.9k%; Δ 587k% < -1%)
CFO/TA -0.40 > 3% & CFO -422.9m > Net Income -464.2m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 15.74 > 1.5 & < 3
Outstanding Shares: last quarter (181.5m) vs 12m ago 23.54% < -2%
Gross Margin: -145.6% > 18% (prev 0.78%; Δ -14.6k% > 0.5%)
Asset Turnover: 0.02% > 50% (prev 0.36%; Δ -0.33% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -15.00
A: 0.93 (Total Current Assets 1.04b - Total Current Liabilities 66.3m) / Total Assets 1.05b
B: -1.52 (Retained Earnings -1.60b / Total Assets 1.05b)
C: -0.65 (EBIT TTM -481.9m / Avg Total Assets 736.7m)
D: -24.09 (Book Value of Equity -1.60b / Total Liabilities 66.3m)
Altman-Z'' Score: -28.55 = D
Beneish M 0.85
DSRI: 6.93 (Receivables 1.64m/2.22m, Revenue 160k/1.50m)
GMI: 1.00 (fallback, negative margins)
AQI: 0.47 (AQ_t 0.01 / AQ_t-1 0.02)
SGI: 0.11 (Revenue 160k / 1.50m)
TATA: -0.04 (NI -464.2m - CFO -422.9m) / TA 1.05b)
Beneish M-Score: 0.85 (Cap -4..+1) = D
What is the price of IMVT shares? As of April 08, 2026, the stock is trading at USD 24.61 with a total of 1,233,311 shares traded.
Over the past week, the price has changed by -0.93%, over one month by -6.82%, over three months by -7.93% and over the past year by +71.02%.
Is IMVT a buy, sell or hold? Immunovant has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy IMVT.
  • StrongBuy: 10
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the IMVT price?
Analysts Target Price 40.2 63.3%
Immunovant (IMVT) - Fundamental Data Overview as of 08 April 2026
P/B = 4.7923
Revenue TTM = 160k USD
EBIT TTM = -481.9m USD
EBITDA TTM = -481.5m USD
Long Term Debt = 98.0k USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 98.0k USD (from shortTermDebt, last fiscal year)
Debt = 98.0k USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -994.4m USD (recalculated: Debt 98.0k - CCE 994.5m)
Enterprise Value = 4.06b USD (5.06b + Debt 98.0k - CCE 994.5m)
 Interest Coverage Ratio = unknown (Ebit TTM -481.9m / Interest Expense TTM 0.0)
 EV/FCF = -9.60x (Enterprise Value 4.06b / FCF TTM -423.1m)
FCF Yield = -10.42% (FCF TTM -423.1m / Enterprise Value 4.06b)
 FCF Margin = -264k% (FCF TTM -423.1m / Revenue TTM 160k)
 Net Margin = -290k% (Net Income TTM -464.2m / Revenue TTM 160k)
 Gross Margin = -145.6% ((Revenue TTM 160k - Cost of Revenue TTM 393k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 3.86 (Enterprise Value 4.06b / Total Assets 1.05b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 98.0k)
Taxrate = 21.0% (US default 21%)
NOPAT = -380.7m (EBIT -481.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 15.74 (Total Current Assets 1.04b / Total Current Liabilities 66.3m)
Debt / Equity = 0.00 (Debt 98.0k / totalStockholderEquity, last quarter 986.1m)
 Debt / EBITDA = 2.07 (negative EBITDA) (Net Debt -994.4m / EBITDA -481.5m)
 Debt / FCF = 2.35 (negative FCF - burning cash) (Net Debt -994.4m / FCF TTM -423.1m)
 Total Stockholder Equity = 705.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -63.01% (Net Income -464.2m / Total Assets 1.05b)
RoE = -65.80% (Net Income TTM -464.2m / Total Stockholder Equity 705.5m)
RoCE = -68.30% (EBIT -481.9m / Capital Employed (Equity 705.5m + L.T.Debt 98.0k))
 RoIC = -53.96% (negative operating profit) (NOPAT -380.7m / Invested Capital 705.5m)
 WACC = 10.14% (E(5.06b)/V(5.06b) * Re(10.14%) + D(98.0k)/V(5.06b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 10.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 12.07%
 [DCF] Fair Price = unknown (Cash Flow -423.1m)
 EPS Correlation: -76.44 | EPS CAGR: -9.63% | SUE: 2.56 | # QB: 1
Revenue Correlation: 6.16 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.81 | Chg7d=-0.010 | Chg30d=-0.010 | Revisions Net=+1 | Analysts=3
EPS next Year (2027-03-31): EPS=-2.62 | Chg7d=-0.050 | Chg30d=+0.048 | Revisions Net=+4 | Growth EPS=-3.7% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: +1.00 (1 Up / 0 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle